By Katherine Hamilton
Shares of iRhythm Technologies declined after the company shared its preliminary revenue for 2024 and financial outlook for 2025.
IRhythm stock fell 8%, to $90.35, midday Monday. It is down 8% over the past six months.
The digital healthcare company said it expects 2024 full-year revenue to be slightly above the high end of its previous guidance, which was $587.5 million.
IRhythm expects revenue for the full year of 2025 to be $675 million to $685 million.
New account openings in the fourth quarter of 2024 hit a record for both Zio monitor and Zio AT.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 13, 2025 12:51 ET (17:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.